VanEck Pharmaceutical ETF
PPH
50 hedge funds and large institutions have $71M invested in VanEck Pharmaceutical ETF in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 5 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
0% more funds holding
Funds holding: 50 → 50 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
13.53% less ownership
Funds ownership: 38.11% → 24.58% (-14%)
32% less capital invested
Capital invested by funds: $105M → $71M (-$33.9M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $313K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$2.43M |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$928K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$922K |
| 4 |
VF
Virtu Financial
New York
|
+$770K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$347K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$22.6M |
| 2 |
Citigroup
New York
|
-$19.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$767K |
| 4 |
CCT
Country Club Trust
Kansas City,
Missouri
|
-$688K |
| 5 |
Morgan Stanley
New York
|
-$642K |
PPH Hedge Fund Activity: Q2 2017 in Review
50 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2017, worth a combined $71M — down 32% from $105M a quarter earlier.
Fund positioning in PPH was balanced in Q2 2017: 5 funds opened new positions, 5 closed out, 16 added to existing stakes and 15 trimmed.
The largest buyer was Raymond James Financial Services Advisors, adding an estimated $2.43M. The largest seller was Goldman Sachs, cutting an estimated $22.6M.
- 50 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $71M of VanEck Pharmaceutical ETF stock for Q2 2017, down 32% quarter-over-quarter.
- 5 funds opened new VanEck Pharmaceutical ETF positions in Q2 2017 and 5 closed out, a net change of 0 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q2 2017 was Raymond James Financial Services Advisors, an estimated $2.43M added.
- The largest VanEck Pharmaceutical ETF seller in Q2 2017 was Goldman Sachs, an estimated $22.6M sold.
Based on aggregated 13F filings for Q2 2017.